SM
IOVA icon

SG3 Management’s Iovance Biotherapeutics IOVA Stock Holding History

SG3 Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-67,000
Closed -$428K – 92
2022
Q4 		$428K Buy
+67,000
New +$523K 0.06% 126
2022
Q1 		– Sell
-19,900
Closed -$380K – 1164
2021
Q4 		$380K Buy
+19,900
New +$438K 0.01% 692

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG3 Management's IOVA Position: Q1 2023 in Review

SG3 Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2023, closing a stake of 67,000 shares — an estimated $428K sold.

SG3 Management first reported a position in IOVA in Q4 2021 and held it in 2 quarters. The position peaked at $428K in Q4 2022. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

  • SG3 Management reported no remaining Iovance Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • SG3 Management sold 67,000 Iovance Biotherapeutics shares in Q1 2023, an estimated $428K.
  • SG3 Management first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 2 quarters.
  • SG3 Management's Iovance Biotherapeutics position peaked at $428K in Q4 2022.
  • 228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.